
Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced details of the methodology and purpose of its Phase I Human Trials with its PulmoBind Molecular Imaging technology for the diagnosis of Pulmonary Embolism and Pulmonary Hypertension. The work will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc.
Click here for full Story http://www.medicalnewstoday.com/articles/107820.php |